TrialPharmacoEconomics2022

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.

Keith W Pratz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.